Anti-Inflammatory Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Biologics), By Indications (Arthritis, Psoriasis, Respiratory Diseases, Multiple Sclerosis, Anti-inflammatory Bowel Disease, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Anti-Inflammatory Therapeutics Market Size

The global anti-inflammatory therapeutics market size was valued at USD 111.78 billion in 2024 and is projected to grow from USD 115.25 billion in 2025 to reach USD 152.78 million by 2033, exhibiting a CAGR of 3.59% during the forecast period (2025-2033).

Anti-inflammatory therapeutics are medications designed to reduce inflammation, a natural response by the body to injury, infection, or conditions such as arthritis and inflammatory bowel disease (IBD). The major factors contributing to the growth of the global anti-inflammatory therapeutics market are the increasing prevalence of inflammatory diseases, ongoing technological advancements in drug delivery systems, and a growing number of regulatory approvals for anti-inflammatory therapeutics.  

These drugs target pathways involved in inflammation to alleviate pain, swelling, and tissue damage. Common categories of anti-inflammatory drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. By reducing inflammation, these therapeutics help manage chronic conditions, improve quality of life, and prevent further complications from prolonged inflammation.

Anti-inflammatory Therapeutics Market Trends

Focus on stem cell therapy

Stem cell therapies are being investigated for their ability to repair damaged tissues and regulate the immune system in chronic inflammatory conditions. By promoting tissue regeneration, stem cells can help restore function in joints and other affected areas. In rheumatoid arthritis (RA) and osteoarthritis, stem cells may reduce inflammation and slow disease progression. These therapies offer the potential for long-term relief by targeting the root causes of inflammation and joint damage.

• For instance, in January 2024, according to news by the University of York, a spin-out company from the University of York is working on developing a novel treatment derived from engineered human stem cells to combat arthritic diseases in both adults and children.

Therefore, stem cells can modulate immune responses, potentially reducing the need for continuous drug treatments.

Digital health and remote monitoring

The integration of digital health tools with anti-inflammatory therapeutics is revolutionizing disease management, offering real-time monitoring of disease progression. Wearable devices now track vital signs, inflammation markers, and physical activity, providing valuable insights into patients' conditions.

Mobile apps allow patients to log symptoms, medication use, and lifestyle factors, enhancing treatment adherence. Moreover, telemedicine solutions enable healthcare providers to adjust therapies remotely, reducing the need for in-person visits.

• In December 2024, bioengineers created implantable sensors for real-time inflammation monitoring, as reported by News Medical & Life Sciences. These advanced tools empower patients to actively manage their condition, prevent flare-ups, and improve long-term outcomes.

By combining these technologies with traditional therapies, personalized care can be better achieved, enhancing the overall management of chronic inflammatory diseases.

Anti-inflammatory Therapeutics Market Drivers

Rising prevalence of inflammatory diseases

The increasing prevalence of inflammatory diseases such as arthritis, inflammatory bowel disease (IBD), and psoriasis is becoming a major global health concern. Alongside this, genetic factors and heightened immune responses have contributed to the rise in autoimmune-related inflammatory disorders. Advances in diagnostic tools and greater awareness are also revealing more cases, particularly among younger populations.

• For example, in September 2024, the University of Queensland published a blog highlighting that rheumatoid arthritis (RA), a chronic and painful inflammatory condition, affects 23 million people globally, with a notably higher incidence among women.

The growing burden of these diseases amplifies the need for effective therapeutic solutions to address inflammation and improve patients' quality of life.

Increased research and development

The surge in research and development (R&D) within the global market has been a driving force behind its growth. Pharmaceutical companies are investing significantly in discovering new compounds and innovative drug delivery systems to enhance the effectiveness and safety of anti-inflammatory treatments.

• For instance, in March 2024, UCB made a strategic equity investment in IMIDomics, Inc., a firm focused on developing treatments for immune-mediated inflammatory diseases (IMIDs).

These R&D efforts are pushing the development of biologics and targeted therapies designed to precisely modulate immune responses, thereby improving patient outcomes in conditions like rheumatoid arthritis and IBD.

Anti-inflammatory Therapeutics Market Restraining Factor

Side effects and safety concerns

Safety concerns and side effects associated with long-term use of anti-inflammatory drugs such as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) present significant challenges. These medications can cause gastrointestinal issues like ulcers, bleeding, and an increased risk of cardiovascular events, including heart attacks and strokes.

Moreover, chronic corticosteroid use may lead to weight gain, bone loss, and hormonal imbalances. Biological therapies, while effective, can suppress the immune system, increasing the risk of infections and other complications. These safety concerns require careful monitoring, which limits the widespread use of certain anti-inflammatory medications.

Anti-inflammatory Therapeutics Market Opportunities

Development of targeted biologic therapies

The advancement of targeted biologic therapies is reshaping the treatment of immune-mediated inflammatory diseases, providing more precise and effective treatment options. These biologics are designed to specifically target immune system components, such as cytokines or immune cells, which play crucial roles in the inflammatory process.

• For instance, in June 2024, the FDA approved VYVGART Hytrulo, a biologic developed by Argenx, for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This approval underscores the growing role of biologics in treating complex inflammatory conditions.

By targeting specific immune pathways, biologics can offer higher precision and reduce the risk of systemic side effects, a significant advantage over traditional therapies. These benefits are driving the growth of the global market as biologics become a cornerstone of modern treatment regimens for chronic inflammatory diseases.

Regional Insights

North America: Dominant region with 31.23% market share

North America leads the global anti-inflammatory therapeutics industry, capturing the largest revenue share due to several critical factors. The region benefits from advanced healthcare infrastructure, a high prevalence of inflammatory diseases, and significant investments in research and development. Strong reimbursement policies further promote the adoption of innovative anti-inflammatory treatments.

Moreover, the presence of major pharmaceutical companies and increased awareness about chronic inflammatory conditions contribute to North America's dominant position in the market. These factors collectively support the region's leadership in advancing therapeutic solutions for inflammatory diseases.  

Asia-Pacific: Rapid growth in China, Japan, and India

Asia Pacific is expected to experience the fastest growth rate. This growth is driven by factors such as increased investments in healthcare infrastructure, a rising aging population, and a higher prevalence of inflammatory diseases like arthritis and inflammatory bowel diseases. Moreover, expanding access to advanced medical technologies and supportive government initiatives are contributing to market expansion. The region is also witnessing an increase in clinical trials for novel anti-inflammatory treatments, further boosting market development.

Countries Insights

• U.S. –The U.S. market thrives on its advanced healthcare infrastructure, substantial health expenditure, and leading pharmaceutical research. The widespread prevalence of inflammatory conditions like arthritis and IBD further fuels growth. For example, in June 2024, AMGEN presented 27 abstracts at the European Alliance of Associations for Rheumatology's (EULAR) Congress, showcasing its commitment to developing novel therapies for inflammatory and rheumatic diseases.
• Canada - Canada’s market is expanding due to improved healthcare access, a large patient population, and increasing cases of autoimmune and inflammatory diseases. In October 2024, Crohn’s & Colitis Canada reported that over 322,000 Canadians are affected by Crohn’s disease or ulcerative colitis, with numbers expected to rise to 470,000 by 2035. This growing patient pool contributes significantly to the market's growth and demand for targeted treatments.
• Germany– Germany's market is driven by its emphasis on healthcare innovation and the high demand for advanced therapies. The country's focus on developing new treatments for chronic inflammatory conditions, coupled with strong investment in research, fuels market expansion. The German market benefits from a well-established healthcare system that supports the use of innovative anti-inflammatory biologics, positioning Germany as a leader in the therapeutic field.
• UK - In the UK, rising awareness and acceptance of innovative therapies among healthcare professionals and patients are propelling the market for anti-inflammatory therapeutics. Additionally, the growing demand for biologics and advancements in immunology research drive market growth. For instance, in February 2024, Queen Mary University of London researchers discovered that RvT4 boosts natural defenses against atherosclerosis in rheumatoid arthritis patients, showcasing the ongoing advancements in immunology that support market growth.
• France - France's anti-inflammatory therapeutics market is influenced by the increasing number of patients with chronic inflammatory diseases. A growing focus on improving these conditions contributes to market expansion. For example, in October 2024, Universite de Lille reported that chronic inflammatory diseases affect 4 million people in France, with the number steadily rising. These diseases, often impacting younger individuals, have significant social and economic consequences, further driving demand for effective treatments.
• China - China's market is expanding due to rapid urbanization, rising healthcare expenditure, and innovative research. The country's large population and growing health awareness further support this growth. In July 2024, Everest Medicines treated its first Chinese patient with zetomipzomib, a novel immunoproteasome inhibitor for lupus nephritis, in the Phase 2b PALISADE trial. This breakthrough highlights China's progress in advancing treatment options for autoimmune diseases, contributing to the market's expansion.
• Japan- Japan’s aging population and increasing prevalence of inflammatory diseases, including anti-inflammatory bowel disease, arthritis, and respiratory conditions, are driving the growth of its market. The demand for advanced therapies to manage these conditions is growing rapidly as Japan continues to address the healthcare needs of an aging demographic. The focus on treatment innovation is further enhancing market development, especially in the field of biologics and immunotherapy.
• India – In India, the market is growing due to the rising prevalence of autoimmune and chronic diseases, an aging population, and lifestyle changes. Improved healthcare access, greater awareness, and the expanding availability of biosimilars are contributing to market growth. India’s robust pharmaceutical manufacturing sector and government support also help make advanced treatments more affordable. In January 2023, Sun Pharma's acquisition of three drug brands expanded its anti-inflammatory portfolio, further boosting market potential.

Segmentation Analysis

The global anti-inflammatory therapeutics market is segmented into drug class, indication, and distribution channel.

By Drug Class

Anti-inflammatory biologics segment dominates the market with the largest market revenue

The anti-inflammatory biologics segment leads the market, driven by their effectiveness in treating chronic inflammatory conditions. Drugs like TNF inhibitors and interleukin inhibitors target specific immune molecules to reduce inflammation, providing relief for patients with conditions unresponsive to NSAIDs or corticosteroids. The rising prevalence of autoimmune disorders and the approval of new biological therapies further boost demand.

• For example, AbbVie’s SKYRIZI (risankizumab-rzaa) was approved by the U.S. FDA in June 2024 for ulcerative colitis treatment, expanding its therapeutic options.

By Indication

Arthritis segment dominates the market with the largest market revenue

Arthritis holds the largest share of the global market due to the growing prevalence of the condition and the effectiveness of anti-inflammatory treatments. Therapies, particularly biologics, have been instrumental in managing symptoms and improving the quality of life for patients.

• In February 2023, the FDA approved Regeneron Pharmaceuticals’ Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR), an inflammatory rheumatic disease. The increasing awareness and availability of advanced therapies, including biologics, are key factors driving market growth.

By Distribution Channel

Hospital pharmacies segment dominates the market with the largest market revenue

Hospital pharmacies dominate the global market primarily due to their role in managing biologic treatments and advanced therapies. Hospitals provide the specialized infrastructure needed for storing and administering biologics, ensuring proper handling and patient care. As treatment centers for severe conditions like rheumatoid arthritis and ulcerative colitis, hospital pharmacies offer expertise in prescribing these advanced medications. Their pivotal role in the treatment of chronic inflammatory conditions solidifies their leadership in the market.

Company Market Share

Key market players are pursuing strategic collaborations, acquisitions, and partnerships to enhance their product offerings and broaden their market reach. These strategic moves help companies expand their portfolios, tap into new markets, and accelerate the development of innovative therapies. For example, partnerships with research institutions enable pharmaceutical companies to access cutting-edge technologies and improve their drug development processes.

Immunic, Inc.: An emerging player in the global anti-inflammatory therapeutics market

Immunic is an emerging player in the anti-inflammatory therapeutics market, focusing on developing oral therapeutics for inflammatory diseases, including autoimmune conditions like ulcerative colitis. The company is advancing its pipeline with innovative treatments that target key immune system pathways, aiming to provide more convenient and effective alternatives to current therapies.

Recent Development:

• In September 2024, Immunic, Inc. revealed significant data at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), showcasing the therapeutic potential of its lead asset, vidofludimus calcium (IMU-838), a Nurr1 activator, for the treatment of multiple sclerosis (MS).

Recent Developments

• July 2024 – Teva Pharmaceuticals and Sanofi provided an update on the timeline for their Duvakitug program, which is focused on investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for the treatment of moderate-to-severe IBD. This collaboration is aimed at advancing targeted therapies for IBD, offering potential benefits for patients with this chronic condition who are in need of more effective treatment options.
• June 2024 - AbbVie announced its acquisition of Celsius Therapeutics, Inc., a privately-owned biotechnology company specializing in innovative therapies for inflammatory diseases. Celsius' leading investigational candidate, CEL383, is a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD)

Analyst Opinion

As per our analyst, the global anti-inflammatory therapeutics market is experiencing robust growth, driven by several pivotal factors. The increasing prevalence of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD), and psoriasis is significantly boosting the demand for effective treatments. Technological advancements in drug development, particularly in biologics and personalized therapies, are improving treatment efficacy and patient outcomes.

However, challenges persist in the form of high treatment costs, particularly for biologics, which can limit access for some patients. Additionally, the complexity of developing and manufacturing biologics and regulatory hurdles continue to be a significant barrier for market players. Despite these challenges, supportive regulatory frameworks and reimbursement policies are contributing to market growth.